Patents by Inventor Jes Thorn Clausen

Jes Thorn Clausen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-HUMAN INTERLEUKIN-20 ANTIBODIES
    Publication number: 20130039923
    Abstract: Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/IL20R2 and IL22R1/IL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treating various diseases and disorders, including autoimmune or inflammatory diseases or disorders.
    Type: Application
    Filed: September 7, 2012
    Publication date: February 14, 2013
    Applicant: Novo Nordisk A/S
    Inventors: Jesper Pass, Søren Østergaard, Jes Thorn Clausen
  • Antibodies against tissue factor pathway inhibitor
    Patent number: 8361469
    Abstract: The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: January 29, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Ida Hilden, Berit Olsen Krogh, Jes Thorn Clausen, Ole Hvilsted Olsen, Jens Breinholt, Brian Lauritzen, Brit Binow Sørensen
  • Anti-human interleukin-20 antibodies
    Patent number: 8287861
    Abstract: Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/IL20R2 and IL22R1/IL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treating various diseases and disorders, including autoimmune or inflammatory diseases or disorders.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: October 16, 2012
    Assignee: Novo Nordisk A/S
    Inventors: Jesper Pass, Søren Østergaard, Jes Thorn Clausen
  • Antibodies Against Tissue Factor Pathway Inhibitor
    Publication number: 20110318356
    Abstract: The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.
    Type: Application
    Filed: December 18, 2009
    Publication date: December 29, 2011
    Applicant: NOVO Nordisk A/S
    Inventors: Ida Hilden, Berit Olsen Krogh, Jes Thorn Clausen, Ole Hvilsted Olsen, Jens Breinholt, Brian Lauritzen, Brit Binow Sørensen
  • Antibodies Against Tissue Factor Pathway Inhibitor (TFPI)
    Publication number: 20110268745
    Abstract: The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce clotting time in (a) human FVIII-deficient plasma and/or (b) human whole blood. Such antibodies have utility in the treatment of bleeding disorders and in the stimulation of blood clotting.
    Type: Application
    Filed: December 18, 2009
    Publication date: November 3, 2011
    Applicant: Novo Nordisk A/S
    Inventors: Ida Hilden, Jes Thorn Clausen
  • Anti-Human Interleukin-20 Antibodies
    Publication number: 20110091475
    Abstract: Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/AL20R2 and IL22R1/AL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treat-ing various diseases and disorders, including autoimmune or inflammatory diseases or disorders.
    Type: Application
    Filed: June 30, 2009
    Publication date: April 21, 2011
    Applicant: Novo Nordisk A/S
    Inventors: Jesper Pass, Soren Østergaard, Jes Thorn Clausen